North East and North Cumbria
ICS Formulary
5 Infections
05-04-01 Treatment of malaria
Dihydroartemisinin / piperaquine phosphate
Eurartesim
®
Formulary
160mg/20mg & 320mg/40mg tablets
Approved for the treatment for plasmodium falciparum malaria in line with current UK and WHO guidelines.
Only available from Newcastle Hospitals (RVI)
Artesunate
Formulary
Approved for severe malaria in in line WHO guidance.
Links
COVID-19 Therapeutic Alert
Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients (Version 5 - effective from 10th February 2022)
MHRA Drug Safety Alert (Nov 2017): Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions
MHRA Drug Safety Alert (Nov 2017): Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions
MHRA Drug Safety Update (Feb 2022): Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
NENC ICB - Cellulitis Diagnosis and Management in Ambulatory Adults in primary care; Supporting Information
NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
NICE NG63: Antimicrobial stewardship: changing risk-related behaviours in the general population
North of Tyne, Gateshead and North Cumbria - Antibiotic and Diagnostic quick reference tools
Primary Care Antimicrobial Guidelines
TEWV: Antibiotic Prescribing Procedure
UK Interim Clinical Commissioning Police - Therapies for patients with symptomatic hospital-onset COVID-19
Key
Full Site